Literature DB >> 2212128

Years of potential life lost: another indicator of the impact of cutaneous malignant melanoma on society.

V A Albert1, H K Koh, A C Geller, D R Miller, M N Prout, R A Lew.   

Abstract

Years of potential life lost (YPLL) is an indicator of premature mortality that complements traditional incidence and mortality rates and that facilitates comparisons among different cancers. We calculated YPLL from cutaneous melanoma and 11 other cancers routinely recorded and tracked by Surveillance, Epidemiology and End Results (SEER). YPLL from cutaneous melanoma ranked eighth for persons younger than 65 years of age and fourth for those 20 to 49 years of age. An average of 17.1 YPLL per death were due to melanoma, one of the highest rates for adult-onset cancers. The results of our study, the first to apply YPLL to cutaneous melanoma, emphasize the disproportionate impact of this cancer on young and middle-aged adults and reemphasize the importance of this cancer as a public health priority.

Entities:  

Mesh:

Year:  1990        PMID: 2212128     DOI: 10.1016/0190-9622(90)70214-3

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  10 in total

1.  The Wilms' tumor suppressor WT1 is associated with melanoma proliferation.

Authors:  Nicole Wagner; John Panelos; Daniela Massi; Kay-Dietrich Wagner
Journal:  Pflugers Arch       Date:  2007-10-03       Impact factor: 3.657

2.  WT1 silencing by RNAi synergizes with chemotherapeutic agents and induces chemosensitization to doxorubicin and cisplatin in B16F10 murine melanoma cells.

Authors:  Pablo Zapata-Benavides; Edgar Manilla-Muñoz; Diana E Zamora-Avila; Santiago Saavedra-Alonso; Moisés A Franco-Molina; Laura M Trejo-Avila; Guillermo Davalos-Aranda; Cristina Rodríguez-Padilla
Journal:  Oncol Lett       Date:  2012-01-19       Impact factor: 2.967

3.  Skin cancer prevention: a time for action.

Authors:  S A Everett; G A Colditz
Journal:  J Community Health       Date:  1997-06

4.  Improving the early detection of malignant melanoma.

Authors:  R Grover; D A Ross; M McKelvie; B D Morgan
Journal:  Ann R Coll Surg Engl       Date:  1996-05       Impact factor: 1.891

Review 5.  Years of potential life lost and indirect costs of melanoma and non-melanoma skin cancer: a systematic review of the literature.

Authors:  Gery P Guy; Donatus U Ekwueme
Journal:  Pharmacoeconomics       Date:  2011-10       Impact factor: 4.981

Review 6.  Screening and early detection of skin cancer.

Authors:  Kenneth G Linden
Journal:  Curr Oncol Rep       Date:  2004-11       Impact factor: 5.075

7.  Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma.

Authors:  Patrick A Ott; Richard D Carvajal; Neeta Pandit-Taskar; Achim A Jungbluth; Eric W Hoffman; Bor-Wen Wu; John S Bomalaski; Ralph Venhaus; Linda Pan; Lloyd J Old; Anna C Pavlick; Jedd D Wolchok
Journal:  Invest New Drugs       Date:  2012-08-05       Impact factor: 3.850

8.  1,3-Bis(3,5-dichlorophenyl) urea compound 'COH-SR4' inhibits proliferation and activates apoptosis in melanoma.

Authors:  Sharad S Singhal; James Figarola; Jyotsana Singhal; Kathryn Leake; Lokesh Nagaprashantha; Christopher Lincoln; B Gabriel Gugiu; David Horne; Richard Jove; Sanjay Awasthi; Samuel Rahbar
Journal:  Biochem Pharmacol       Date:  2012-08-28       Impact factor: 5.858

9.  Uncertainty quantification of years of potential life lost-based estimates from mortality data summarized as death counts within age intervals.

Authors:  Jay J Xu; Thomas R Belin; Christina M Ramirez
Journal:  Ann Epidemiol       Date:  2020-11-19       Impact factor: 6.996

10.  Racial and Ethnic Disparities in Years of Potential Life Lost Attributable to COVID-19 in the United States: An Analysis of 45 States and the District of Columbia.

Authors:  Jay J Xu; Jarvis T Chen; Thomas R Belin; Ronald S Brookmeyer; Marc A Suchard; Christina M Ramirez
Journal:  Int J Environ Res Public Health       Date:  2021-03-12       Impact factor: 3.390

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.